Literature DB >> 21168817

The impact of intravitreal bevacizumab therapy on choroidal melanoma.

Breno R Lima1, Lynn R Schoenfield, Arun D Singh.   

Abstract

PURPOSE: To describe the clinical course and ancillary findings of 3 patients with choroidal melanoma who inadvertently received multiple intravitreal injections of bevacizumab for a presumed diagnosis of choroidal neovascular membrane.
DESIGN: Observational case series.
METHODS: Three patients with choroidal melanomas who received a series of monthly intravitreal injections of bevacizumab for presumed choroidal neovascularization were evaluated. Clinical, ultrasonographic, and angiographic findings are presented. Histopathologic features are correlated with clinical features in 2 patients who underwent enucleation.
RESULTS: Lack of benefit in halting tumor progression was observed in all 3 cases. In 2 cases treated with enucleation, there was evidence of bevacizumab-induced gliotic/fibrotic retinal changes.
CONCLUSIONS: We present 3 cases of choroidal melanomas that showed progression while patients received multiple intravitreal injections of bevacizumab. The use of the drug led to the formation of a gliotic/fibrotic membrane that resulted in masking of the underlying tumor and consequently delayed the correct diagnosis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21168817     DOI: 10.1016/j.ajo.2010.08.040

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  12 in total

1.  Ranibizumab for the Prevention of Radiation Complications in Patients Treated With Proton Beam Irradiation for Choroidal Melanoma.

Authors:  Ivana K Kim; Anne Marie Lane; Purva Jain; Caroline Awh; Evangelos S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

Review 2.  Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Authors:  Patrick Oellers; Prithvi Mruthyunjaya
Journal:  Melanoma Manag       Date:  2016-02-17

3.  Rapid growth of primary uveal melanoma following intravitreal bevacizumab injection: a case report and review of the literature.

Authors:  Jingyi Ma; Kelsey A Roelofs; Laurie Russell; Ezekiel Weis; Sylvia H Chen
Journal:  Digit J Ophthalmol       Date:  2020-07-03

4.  Growth of Uveal Melanoma following Intravitreal Bevacizumab.

Authors:  Jasmine H Francis; Jonathan Kim; Amy Lin; Robert Folberg; Saipriya Iyer; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2016-11-12

5.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

Review 6.  Anti-vascular endothelial growth factor indications in ocular disease.

Authors:  Stefan Cornel; Iliescu Daniela Adriana; Timaru Cristina Mihaela; Schmitzer Speranta; De Simone Algerino; Batras Mehdi; Hosseini-Ramhormozi Jalaladin
Journal:  Rom J Ophthalmol       Date:  2015 Oct-Dec

7.  Progression of choroidal metastasis of ovarian serous cystoadenocarcinoma after intravitreal bevacizumab treatment.

Authors:  Irene C Kuo; Ruben H Sambuelli; Javier Bono; Ricardo J Smith; Victor E Reviglio
Journal:  Rare Tumors       Date:  2013-03-04

8.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22

Review 9.  Anti-VEGF Therapy and the Retina: An Update.

Authors:  Vikas Tah; Harry O Orlans; Jonathan Hyer; Edward Casswell; Nizar Din; Vishnu Sri Shanmuganathan; Louise Ramskold; Saruban Pasu
Journal:  J Ophthalmol       Date:  2015-08-31       Impact factor: 1.909

10.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.